Obesity and hypertension

被引:493
作者
Seravalle, Gino [1 ]
Grassi, Guido [2 ]
机构
[1] Ist Auxol Italiano IRCCS, Cardiol Dept, S Luca Hosp, Milan, Italy
[2] Univ Milano Bicocca, Med Clin, S Gerardo Hosp, Monza, Italy
关键词
Visceral fat distribution; Hypertension; Cardiovascular risk; Target organ damage; Pathophysiological mechanisms; Treatment; SMALL-ARTERY STRUCTURE; BODY-FAT DISTRIBUTION; BLOOD-PRESSURE; CARDIOVASCULAR RISK; INSULIN-RESISTANCE; METABOLIC COMPLICATIONS; SYMPATHETIC ACTIVATION; REFLEX ABNORMALITIES; CLOSE CORRELATION; WORKING GROUP;
D O I
10.1016/j.phrs.2017.05.013
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Obesity and in particular the excessive visceral fat distribution is accompanied by several alterations at hormonal, inflammatory and endothelial level. These alterations induce a stimulation of several other mechanisms that contribute to the hypertensive state and on the other side to increase the cardiovascular morbidity. In these chapter we will examine the main mechanisms of obesity and obesity-related hypertension and in particular the role of sympathetic nervous system, the alterations of the renal function and at the microvascular level. We will also depict the role of insulin resistance as factor stimulating and potentiating the other mechanisms. The second part will be focalized on the major target organ damage linked with obesity and obesity-related hypertension. We will finally describe the management and treatment of obesity and the antihypertensive drug therapies more effective in hypertensive obeses. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 82 条
  • [1] Cardiac remodeling in obesity
    Abel, E. Dale
    Litwin, Sheldon E.
    Sweeney, Gary
    [J]. PHYSIOLOGICAL REVIEWS, 2008, 88 (02) : 389 - 419
  • [2] Subcutaneous obesity is not associated with sympathetic neural activation
    Alvarez, GE
    Ballard, TP
    Beske, SD
    Davy, KP
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2004, 287 (01): : H414 - H418
  • [3] Leptin, Not Adiponectin, Predicts Hypertension in the Copenhagen City Heart Study
    Asferg, Camilla
    Mogelvang, Rasmus
    Flyvbjerg, Allan
    Frystyk, Jan
    Jensen, Jan S.
    Marott, Jacob L.
    Appleyard, Merete
    Jensen, Gorm B.
    Jeppesen, Jorgen
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 2010, 23 (03) : 327 - 333
  • [4] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
    Astrup, A.
    Carraro, R.
    Finer, N.
    Harper, A.
    Kunesova, M.
    Lean, M. E. J.
    Niskanen, L.
    Rasmussen, M. F.
    Rissanen, A.
    Rossner, S.
    Savolainen, M. J.
    Van Gaal, L.
    [J]. INTERNATIONAL JOURNAL OF OBESITY, 2012, 36 (06) : 843 - 854
  • [5] Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension
    Bakris, G
    Calhoun, D
    Egan, B
    Hellmann, C
    Dolker, M
    Kingma, I
    [J]. JOURNAL OF HYPERTENSION, 2002, 20 (11) : 2257 - 2267
  • [6] Major Role for Hypoxia Inducible Factor-1 and the Endothelin System in Promoting Myocardial Infarction and Hypertension in an Animal Model of Obstructive Sleep Apnea
    Belaidi, Elise
    Joyeux-Faure, Marie
    Ribuot, Christophe
    Launois, Sandrine H.
    Levy, Patrick
    Godin-Ribuot, Diane
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (15) : 1309 - 1317
  • [7] Boillot A, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0052708, 10.1371/journal.pone.0064417]
  • [8] Serum Uric Acid and Cardiometabolic Disease Another Brick in the Wall?
    Borghi, Claudio
    Francesco, Arrigo
    Cicero, Giuseppe
    [J]. HYPERTENSION, 2017, 69 (06) : 1011 - 1013
  • [9] Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity
    Boudina, S
    Sena, S
    O'Neill, BT
    Tathireddy, P
    Young, ME
    Abel, ED
    [J]. CIRCULATION, 2005, 112 (17) : 2686 - 2695
  • [10] Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension
    Brunner, H
    Cockcroft, JR
    Deanfield, J
    Donald, A
    Ferrannini, E
    Halcox, J
    Kiowski, W
    Luscher, TF
    Mancia, G
    Natali, A
    Oliver, JJ
    Pessina, AC
    Rizzoni, D
    Rossi, GP
    Salvetti, A
    Spieker, LE
    Taddei, S
    Webb, DJ
    [J]. JOURNAL OF HYPERTENSION, 2005, 23 (02) : 233 - 246